CLINUVEL Expands SCENESSE® Distribution to Argentina

Clinuvel Pharmaceuticals Limited ( (AU:CUV) ) has issued an announcement.

CLINUVEL has entered a distribution agreement with Diligens Salud SA, part of the Scienza Group, to distribute SCENESSE® in Argentina, targeting patients with erythropoietic protoporphyria (EPP). This agreement aims to expand patient access under Argentina’s Exception Regime for Access to Non-Registered Drugs. The collaboration is part of CLINUVEL’s broader strategy to provide early access to SCENESSE® globally, leveraging named-patient programs and working towards formal marketing authorizations in new markets. This move is expected to improve the quality of life for EPP patients in Argentina and strengthen CLINUVEL’s presence in Latin America.

More about Clinuvel Pharmaceuticals Limited

CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical company based in Melbourne, Australia, focusing on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders. The company is a leader in photomedicine and melanocortin peptide research, with its lead therapy, SCENESSE®, being the first systemic photoprotective drug approved to prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP). CLINUVEL operates in Europe, Singapore, and the USA.

YTD Price Performance: -6.13%

Average Trading Volume: 404

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $368.5M

See more data about CUV stock on TipRanks’ Stock Analysis page.